# US 11,078,236 B2 · Selenium-based therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,236 B2
- Document ID: US11078236B2
- Status: Granted
- Kind: B2
- Application number: 15/969,742
- Filed: 2018-05-02
- Published: 2018-11-15
- Granted: 2021-08-03
- Earliest claimed: 2017-05-02
- Assignees: Burke Neurological Institute
- Applicants: Burke Neurological Institute
- Inventors: Rajiv R Ratan; Ishraq Alim, I; Saravanan Karuppagounder
- Web page: https://patentgrep.com/patent/US11078236B2

## CPC

- C07K 14/001: {by chemical synthesis}
- A61K 31/095: Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/47: from mammals
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

## Claims

### Claim 1

A compound comprising:
(a) a selenium-containing portion, wherein the selenium-containing portion consists of a C-terminus domain selenoprotein P fragment consisting of the sequence UKUNLN (SEQ ID NO:28);
(b) linked to a Tat transduction domain.

### Claim 2 (depends on 1)

The compound of claim 1, further comprising in addition to (a) and (b), a portion (c) which is a sequence fragment selected from the group consisting of NA1, PTP-Sigma, GluR2, SDK-5, and SS31.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound consists of SEQ ID NO:2.